Moderate riskFDA DeviceClass II

Accriva Diagnostics directCHECK ACT-LR quality control recalled for incorrect labeling

Accriva Diagnostics' directCHECK ACT-LR whole blood quality control product (level 2, lot A6DLA001) has incorrect performance range information on its label. This labeling error could lead to misinterpretation of test results if the correct reference range is not known.

From the FDA notice · Read the official notice ↗ · All Accriva Diagnostics recalls

What to do

  1. Check if your laboratory uses directCHECK ACT-LR level 2 from lot A6DLA001
  2. Contact Accriva Diagnostics or your supplier for corrected labeling or instructions
  3. Do not use the product until you have confirmed the correct performance range with the manufacturer

Is yours affected?

Compare your label or packaging with the recalled product.

Product
directCHECK ACT-LR whole blood quality control, level 2 Model/Catalog Number: DCGLR-2
Sold in
Nationwide
Made for
All ages (0 months and older)

Details

Units affected
6060
Illnesses reported
None reported
Manufactured in
6260 Sequence Dr, San Diego, CA, United States
Classification
Class II
Recall number
Z-2460-2026

In the FDA's words

Description
directCHECK ACT-LR whole blood quality control, level 2 Model/Catalog Number: DCGLR-2 Assayed Whole blood control contains labeling with incorrect performance range. Lot #: A6DLA001 Unique Device Identifier: 10711234170373 Distribution: Worldwide - US Nationwide distribution including in the states of AL, AR, AZ, CA, FL, GA, ID, IL, IN, KY, MA, MD, MI, MN, MO, MT, NC, NJ, NM, NY, OH, OK, PA, SC, TN, TX, VA, VT, WA, WI, WV and the countries of Canada, Hong Kong, Spain. Affected quantity: 6060
Hazard
Assayed Whole blood control contains labeling with incorrect performance range.

More from Accriva Diagnostics

See all

Related topics